Really Doug ?
I think Doug Miehm has it wrong yet again, and just isnt getting the relevance of this FDA news. I bet that Cooper / RIdgeway / Lowe get it right. The announcement today that we are going to get a direct compare look on 4050 Monotherapy as part of this FDA approved trial is a big deal. When you combine that with the fact that enrollemnt is open to cohorts / patient groups from mild to severe cases... and wont be limited to those who dont tolerate the other current standards of care..... the enrollment should be substantially quicker and easier... The fact that the drug to drug interaction data has been vetted and accepted and that cohort eliminated speaks volumes. Perhaps most importantly, the monotherapy trial results will be a much more direct comparison to both the incumbent's data giving Prometic potentially extremely important data set. Data that people will prepay for. When you add in the fact that there has been far more positive activity in the the stock from US Brokers and Institutions since the new year turned.... I think the writing is on the wall. These guys are FINALLY getting noticed. This is a great setup for a Nasdaq list.... which makes this KOL luncheon and the related exposure that much more interesting. Give us $150mm on the books from a Nasdaq list, $125mm from a Voucher monetization... and an FDA approval.... and the landscape looks much much different. I expect unlike past conferences that there will be some buying coming on the back of this KOL, just as we have seen since the Morgan Stanley conference... This is all made even more interesting if some of these guys are smelling the FEES and Opportunity that will arise out of a move to the US and the inevitable valuation lift that will come with that, the US guys are smart enough and aggressive enough to get out in front of that.